Axsome Therapeutics, Inc. (AXSM)
$162.22+3.77%Close
SELLCRISIS · day 16
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $8.3B
- Beta
- 0.60
- P/E (TTM)
- -43.26
- Short % float
- 7.59%
- Days to cover
- 4.4
- SI change
- +5.3%
- 1W
- -6.21%
- 1M
- -20.51%
- vs SPY 1W
- -5.23%
- vs SPY 1M
- -22.37%
Industry peers
FMP comparable companies · ranked by market cap
- NBIXSELLNeurocrine Biosciences, Inc.$14.3BRECOVERYQ 16$142.44+0.58%
- JAZZSELLJazz Pharmaceuticals plc$13.7BBEARQ 24$218.42-0.35%
- PRAXSELLPraxis Precision Medicines, Inc.$7.2BCRISISQ 10$259.86-1.78%
- DFTXSELLDefinium Therapeutics, Inc.$4.9BBEARQ 26$36.90-0.41%
- XENESELLXenon Pharmaceuticals Inc.$3.5BCRISISQ 22$36.44-1.51%
- DNLISELLDenali Therapeutics Inc.$3.1BCRISISQ 8$19.45-2.88%
- SUPNSELLSupernus Pharmaceuticals, Inc.$2.5BRECOVERYQ 26$42.67-4.36%
- RAPPSELLRapport Therapeutics, Inc. Common Stock$1.5BCRISISQ 23$30.65-2.28%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on AXSM?
- LOPJLB’s latest quantitative signal on Axsome Therapeutics, Inc. (AXSM) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is AXSM in?
- Axsome Therapeutics, Inc. (AXSM) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Axsome Therapeutics, Inc. (AXSM) do?
- Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depres…